Dosing and Formulation Considerations for Toujeo (Insulin Glargine 300 U/mL)

Pharmacologic Equivalence and Dose Adjustment

• Toujeo is not bioequivalent to insulin glargine 100 U/mL; therefore, unit‑for‑unit conversion is inappropriate, and clinicians should adjust the basal dose and reinforce glucose monitoring when patients switch formulations【1】.

Delivery Device and Safety

• Toujeo is supplied exclusively in prefilled pens, a design intended to reduce dosing errors that are more common with concentrated insulin preparations【1】【2】.

Basal‑Only Activity Profile

• Toujeo provides primarily basal insulin coverage with minimal prandial effect, distinguishing it from U‑500 regular insulin, which exhibits both basal and prandial activity【1】.